The FDA Peripheral and Central Nervous System Drugs Advisory Committee unanimously voted that donanemab shows clinical benefit for the treatment of early Alzheimer's disease. - If approved, donanemab would become the second disease-modifying drug for Alzheimer's to receive full approval, expanding the arsenal of available drugs needed to treat Alzheimer's with combination therapy.
10 juin 2024
FDA Approves Rytelo (imetelstat) for the Treatment of Adult Patients with Lower-Risk MDS with Transf
Approval Date: June 6, 2024 Trade Name (Generic Name): Rytelo™ (imetelstat) Approved For: Treatment of adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent...
6 juin 2024
Considering both efficacy and side effects, Ubrogepant is effective for immediate symptom management with known, manageable side effects at recommended doses. Atogepant would appeal to those requiring prophylactic treatment, with efficacy and side effects assessed over longer-term usage. Given these points, choosing between the two should be tailored to the treatment intent (acute vs. preventive) and the patient’s health profile.
2 nov. 2023
the U.S. Food and Drug Administration (FDA) granted approval for Yesafili (aflibercept-jbvf), an interchangeable biosimilar to Eylea (aflibercept). Aflibercept products function by inhibiting vascular endothelial growth factor (VEGF), which hinders abnormal blood vessel growth in the eye. By blocking VEGF, these products can slow down or reduce damage to the retina and help preserve vision
23 mai 2024
